Recommendations for the Outpatient Drug Treatment of Patients With COVID-19.


Journal

Deutsches Arzteblatt international
ISSN: 1866-0452
Titre abrégé: Dtsch Arztebl Int
Pays: Germany
ID NLM: 101475967

Informations de publication

Date de publication:
13 05 2022
Historique:
received: 06 04 2022
revised: 06 04 2022
accepted: 13 04 2022
pubmed: 5 5 2022
medline: 19 8 2022
entrez: 4 5 2022
Statut: ppublish

Résumé

One of the purposes of outpatient treatment for COVID-19 patients is to prevent severe disease courses and hospitalization. There is a need for evidence-based recommendations to be applied in primary care and specialized outpatient settings. This guideline was developed on the basis of publications that were retrieved by a systematic search for randomized controlled trials in the Cochrane COVID-19 trial registry. The quality of evidence was assessed with GRADE, and structured consensus generation was carried out with MAGICapp. Unvaccinated COVID-19 outpatients with at least one risk factor for a severe disease course may be treated in the early phase of the disease with sotrovimab, remdesivir, or nirmatrelvir/ritonavir. Molnupiravir may also be used for such patients if no other clinically appropriate treatment options are available. Immunosuppressed persons with COVID-19 who are at high risk, and whose response to vaccination is expected to be reduced, ought to be treated with sotrovimab. It should be noted, however, that the clinical efficacy of sotrovimab against infections with the omicron subtype BA.2 is uncertain at the currently used dose, as the drug has displayed reduced activity against this subtype in vitro. COVID-19 patients at risk of a severe course may be offered budesonide inhalation, according to an off-label recommendation of the German College of General Practitioners and Family Physicians (other medical societies do not recommend either for or against this treatment). Thrombo - embolism prophylaxis with low-molecular-weight heparin may be given to elderly patients or those with a pre-existing illness. No recommendation is made concerning fluvoxamine or colchicine. Acetylsalicylic acid, azithromycin, ivermectin, systemic steroids, and vitamin D should not be used for the outpatient treatment of COVID-19. Drug treatment is now available for outpatients with COVID-19 in the early phase. Nearly all of the relevant trials have been conducted in unvaccinated subjects; this needs to be kept in mind in patient selection.

Sections du résumé

BACKGROUND
One of the purposes of outpatient treatment for COVID-19 patients is to prevent severe disease courses and hospitalization. There is a need for evidence-based recommendations to be applied in primary care and specialized outpatient settings.
METHODS
This guideline was developed on the basis of publications that were retrieved by a systematic search for randomized controlled trials in the Cochrane COVID-19 trial registry. The quality of evidence was assessed with GRADE, and structured consensus generation was carried out with MAGICapp.
RESULTS
Unvaccinated COVID-19 outpatients with at least one risk factor for a severe disease course may be treated in the early phase of the disease with sotrovimab, remdesivir, or nirmatrelvir/ritonavir. Molnupiravir may also be used for such patients if no other clinically appropriate treatment options are available. Immunosuppressed persons with COVID-19 who are at high risk, and whose response to vaccination is expected to be reduced, ought to be treated with sotrovimab. It should be noted, however, that the clinical efficacy of sotrovimab against infections with the omicron subtype BA.2 is uncertain at the currently used dose, as the drug has displayed reduced activity against this subtype in vitro. COVID-19 patients at risk of a severe course may be offered budesonide inhalation, according to an off-label recommendation of the German College of General Practitioners and Family Physicians (other medical societies do not recommend either for or against this treatment). Thrombo - embolism prophylaxis with low-molecular-weight heparin may be given to elderly patients or those with a pre-existing illness. No recommendation is made concerning fluvoxamine or colchicine. Acetylsalicylic acid, azithromycin, ivermectin, systemic steroids, and vitamin D should not be used for the outpatient treatment of COVID-19.
CONCLUSION
Drug treatment is now available for outpatients with COVID-19 in the early phase. Nearly all of the relevant trials have been conducted in unvaccinated subjects; this needs to be kept in mind in patient selection.

Identifiants

pubmed: 35506263
pii: arztebl.m2022.0203
doi: 10.3238/arztebl.m2022.0203
pmc: PMC9468468
doi:
pii:

Substances chimiques

Antibodies, Monoclonal, Humanized 0
Antibodies, Neutralizing 0
sotrovimab 1MTK0BPN8V

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

342-349

Références

Lancet. 2021 Sep 4;398(10303):843-855
pubmed: 34388395
Cell. 2022 Feb 3;185(3):447-456.e11
pubmed: 35026151
N Engl J Med. 2022 May 5;386(18):1700-1711
pubmed: 35353960
Lancet Respir Med. 2021 Jul;9(7):763-772
pubmed: 33844996
Cochrane Database Syst Rev. 2021 Oct 18;10:CD015045
pubmed: 34658014
Cochrane Database Syst Rev. 2021 Jul 28;7:CD015017
pubmed: 34318930
N Engl J Med. 2022 Jan 27;386(4):305-315
pubmed: 34937145
J Antimicrob Chemother. 2021 Nov 12;76(12):3286-3295
pubmed: 34450619
N Engl J Med. 2021 Nov 18;385(21):1941-1950
pubmed: 34706189
JAMA Intern Med. 2022 Jan 1;182(1):42-49
pubmed: 34807241
Dtsch Arztebl Int. 2022 Apr 15;119(15):263-269
pubmed: 35302484
Cochrane Database Syst Rev. 2021 Oct 22;10:CD015025
pubmed: 34679203
Lancet Glob Health. 2022 Jan;10(1):e42-e51
pubmed: 34717820
JAMA. 2020 Dec 8;324(22):2292-2300
pubmed: 33180097
J Clin Epidemiol. 2011 Apr;64(4):401-6
pubmed: 21208779
BMJ. 2016 Jun 28;353:i2016
pubmed: 27353417
N Engl J Med. 2022 Feb 10;386(6):509-520
pubmed: 34914868
Cochrane Database Syst Rev. 2021 May 24;5:CD015043
pubmed: 34029377
JAMA. 2021 Nov 2;326(17):1703-1712
pubmed: 34633405
Clin Infect Dis. 2022 Aug 24;75(1):e473-e481
pubmed: 34523673
Cochrane Database Syst Rev. 2021 Aug 16;8:CD014963
pubmed: 34396514
Sci Transl Med. 2022 Jan 19;14(628):eabl7430
pubmed: 34941423
N Engl J Med. 2022 Apr 14;386(15):1397-1408
pubmed: 35172054

Auteurs

Hanna Kaduszkiewicz (H)

Institute of General Medicine, Christian Albrechts University of Kiel; Emeritus, University Medical Center Göttingen; Institute of General Medicine, Faculty of Medicine, University Medical Center Freiburg; Department of Intensive Care Medicine, Hamburg-Eppendorf University Hospital; Department I of Internal Medicine, Division of Infectious Diseases, Faculty of Medicine and University Hospital Cologne, University of Cologne; Medical Clinic and Polyclinic for Anesthesiology, Intensive Care, Emergency Medicine and Pain Therapy, University Hospital of Würzburg; Department I of Internal Medicine, Evidence-Based Oncology, Faculty of Medicine and University Hospital of Cologne, University of Cologne; *See eBox for members of the guideline group and the consensus conference (collaborators).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH